Table 1 Demographic, clinical, laboratory and transient elastography findings according to the inflammatory bowel disease type (Crohn’s disease and ulcerative colitis)
Variables | All patients (n = 168) | Crohn’s disease (n = 107, 63.7%) | Ulcerative colitis (n = 61, 36.3%) | P value |
|---|---|---|---|---|
Demographics | ||||
Mean age ± SD – years | 40.1 ± 12.6 | 38.4 ± 11.9 | 43.3 ± 13.4 | 0.234 |
White race– n, (%) | 168 (100) | 107 (100) | 61 (100) | 1.0 |
Female sex – n, (%) | 90 (53.6) | 57 (53.3) | 33 (54.1) | 1.0 |
IBD related factors | ||||
Montreal classification – n, (%) | ||||
A1, A2, A3 | - | 8(7.5); 75(70.1); 24(22.4) | - | - |
L1, L2, L3 | - | 56 (52.3); 10(9.3); 41(38.3) | - | - |
L4 | - | 0 | - | - |
B1, B2, B3 | - | 48(44.9);36(33.6);23(21.5) | - | - |
Perianal disease | - | 32 (29.9) | 0 | < 0.001 |
Disease extension – n, (%) | ||||
E1 | ||||
E2 | - | - | 17 (27.9) | |
E3 | - | - | 18 (29.5) | - |
Mean Age at IBD diagnosis ± | - | - | 26 (42.6) | - |
SD– years | 33.3 ± 12.3 | 30.9 ± 11.6 | 37.3 ± 12.6 | - |
Median IBD duration (IQR) – | 72.0 (84.0) | 72.0 (108) | 72.0 (78) | 0.454 |
months | 56 (33.3) | 38 (35.5) | 18 (29.5) | 0.851 |
Tobacco use – n, (%) | 34 (20.2) | 34 (31.8) | 0 | 0.497 |
IBD-related abdominal surgery – n, (%) | 16 (9.5) | 10 (9.3) | 6 (9.8) | < 0.001 |
Family history of IBD – n, (%) | 74 (44.0) | 22 (20.6) | 52 (85.2) | 1.000 |
Mesalazine – n, (%) | 82 (48.8) | 60 (56.1) | 22 (36.1) | < 0.001 |
Immunomodulators* – n, (%) | 6 (3.6) | 3 (2.8) | 3 (4.9) | 0.024 |
Glucocorticoids – n, (%) | 68 (40.5) | 49 (45.8) | 19 (31.1) | 1.000 |
Biologic therapy – n, (%) | 0.073 | |||
Anthropometric data | ||||
Mean weight ± SD – kg | 69.1 ± 12.5 | 70.7 ± 13.5 | 66.4 ± 10.2 | 0.033 |
Mean height ± SD – cm | 166.1 ± 9.2 | 167.0 ± 9.5 | 164.6 ± 8.5 | 0.106 |
Mean BMI ± SD – kg/m2 | 25.1 ± 4.0 | 25.5 ± 4.2 | 24.5 ± 3.4 | 0.122 |
Mean waist circumference ± SD – cm | 87.5 ± 11.5 | 88.4 ± 12.1 | 85.9 ± 10.1 | 0.183 |
Laboratorial data | ||||
Mean Hemoglobin ± SD – g/dL | 14.0 ± 1.3 | 13.9 ± 1.1 | 14.1 ± 1.5 | 0.299 |
Median Leucocyte count (IQR) – x103μL | 6.9 (2.7) | 6.8 (2.6) | 7.2 (3.0) | 0.872 |
Mean Platelet count ± SD – x103μL | 270.7 ± 80.9 | 272.6 ± 91.0 | 267.2 ± 84.7 | 0.678 |
Median FPG (IQR) – mg/dL | 89.0 (16.8) | 88.0 (16.0) | 89.0 (15.5) | 0.626 |
Median AST (IQR) – IU/L | 18.0 (10.0) | 18.0 (10.0) | 16.0 (12.0) | 0.231 |
Median ALT (IQR) – IU/L | 26.0 (16.0) | 26.0 (16.0) | 26.0 (17.5) | 0.9 |
Median G-GT (IQR) – IU/L | 22.0 (19.0) | 22.0 (21.0) | 24.0 (18.5) | 0.575 |
Median AP (IQR) – IU/L | 64.0 (20.8) | 64.0 (21.0) | 64.0 (22.0) | 0.449 |
Median albumin (IQR) – g/dL | 3.8 (0.5) | 3.8 (0.5) | 4.0 (0.5) | 0.052 |
Median total bilirubin (IQR) – mg/dL | 0.5 (0.3) | 0.5 (0.4) | 0.5 (0.3) | 0.665 |
Median direct bilirubin (IQR) – mg/dL | 0.1 (0.1) | 0.1 (0.1) | 0.1 (0.1) | 0.537 |
Mean total cholesterol ± SD – mg/dL | 175.5 ± 13.1 | 175.2 ± 35.2 | 175.9 ± 34.6 | 0.905 |
Mean LDL ± SD – mg/dL | 97.0 ± 28.0 | 94.0 ± 28.0 | 102.3 ± 27.7 | 0.066 |
Mean HDL ± SD – mg/dL | 54.3 ± 13.6 | 54.9 ± 14.2 | 53.2 ± 12.5 | 0.459 |
Median triglycerides (IQR) – mg/dL | 109.0 (70.8) | 117.0 (72.0) | 92.0 (58.0) | 0.026 |
Median CRP (IQR) – mg/L | 2.9 (2.0) | 2.9 (2.8) | 2.9 (0.3) | 0.066 |
Median ESR (IQR) – mm | 10.0 (12.8) | 10.0 (13.0) | 9.0 (12.5) | 0.578 |
Median Calprotectin (IQR) – μg/g | 184.0 (559.3) | 184.0 (404.0) | 197 (741.5) | 0.716 |
Steatosis scores | ||||
Median MAFLD-S (IQR) | -1.9 (4.1) | -1.6 (4.2) | -2.1 (4.2) | 0.245 |
Mean FLI ± SD | 33.9 ± 26.3 | 36.6 ± 27.3 | 29.2 ± 23.9 | 0.079 |
Median HSI (IQR) | 38.1 (8.7) | 38.0 (9.0) | 39.4 (9.1) | 0.338 |
Mean CPN-CD ± SD | - 0.6 ± 1.8 | - 0.5 ± 1.5 | - 0.7 ± 1.3 | 0.314 |
TE | ||||
Median LSM (IQR) – kPa | 4.6 (1.8) | 4.5 (1.7) | 4.7 (1.9) | 0.567 |
Mean IQR/M ± SD – % | 14.0 ± 8.8 | 14.2 ± 6.0 | 14.5 ± 6.3 | 0.213 |
Mean CAP ± SD – dB/m | 249.0 (55.9) | 249.8 ± 59.1 | 247.6 ± 50.3 | 0.807 |
MAFLD criteria | ||||
MAFLD – n, (%) | 65 (38.7) | 46 (43.0) | 19 (31.1) | 0.141 |
Lean MAFLD – n, (%) | 6 (3.6) | 3 (2.8) | 3 (4.9) | 0.669 |
CAP > 248 dB/m – n, (%) | 77 (45.8) | 52 (48.6) | 25 (41.0) | 0.421 |
Overweight/Obesity – n, (%) | 76 (45.2) | 55 (51.4) | 21 (34.4) | 0.037 |
T2DM – n, (%) | 10 (6.0) | 5 (4.7) | 5 (8.2) | 0.499 |
Impaired fasting glycemia – n, (%) | 21 (12.5) | 12 (11.2) | 9 (14.8) | 0.628 |
Abnormal waist circumference – n, (%) | 51 (30.4) | 38 (35.5) | 13 (21.3) | 0.058 |
Dyslipidemia – n, (%) | 53 (31.5) | 29 (27.1) | 24 (39.3) | 0.121 |
Arterial Hypertension – n, (%) | 20 (11.9) | 10 (9.3) | 10 (16.4) | 0.217 |
Plasma CRP > 2 mg/L – n, (%) | 58 (34.5) | 42 (39.3) | 16 (26.2) | 0.095 |